Deep Bio Secures Spot in South Korean Government's Prestigious "Super Gap Startup 1000+" Program
Seoul, Korea (PRWEB) July 07, 2023 -- Deep Bio Inc., a leader in artificial intelligence (AI)-powered cancer diagnostics, has been selected for the South Korean government's "Super Gap Startup 1000+" program. As a result of this selection, Deep Bio will receive up to 600 million KRW in funding over the next three years to drive its commercialization efforts.
An award ceremony was held on July 4th, where Director Byeonggweon Lee from the Korean Ministry of SMEs and Startups (MSS) presented a plaque and expressed confidence in Deep Bio’s potential. “We hold high expectations for Deep Bio's ability to revolutionize healthcare through their exceptional technological prowess.” He affirmed his commitment to supporting companies like Deep Bio by adding, "I will prioritize the needs of these innovative enterprises and ensure their growth by lending an ear to voices in this field."
The "Super Gap Startup 1000+" program is a national initiative aimed to foster high-tech startups that demonstrate unparalleled technological capabilities across 10 key industries. A super gap refers to a wide lead a market leader has over its competitors. Startups were selected based on rigorous evaluations conducted by a distinguished panel of experts from academia, industry, and investment firms. This program, backed by public-private partnerships, has earmarked an unprecedented funding of over 2 trillion KRW over the next 5 years. Deep Bio's selection for this highly competitive program validates its innovative AI-powered cancer diagnostic technology.
"We are honored to be selected for the Super Gap Startup 1000+" program," said Sun Woo Kim, the CEO and Founder of Deep Bio. "This selection is a testament to our innovative technology and our unwavering dedication to advancing unmet needs in noy only digital pathology, but in the wider landscape of healthcare. We will use this funding to accelerate our commercialization efforts and bring our products to more patients around the world.”
Deep Bio's pioneering technology utilizes AI to identify and categorize cancer cells in digitized biopsy images. Their diagnostic software tools aim to optimize cancer diagnostic workflows, empowering pathologists to enhance accuracy and reduce turnaround times, ultimately improving patient outcomes.
Deep Bio has already obtained regulatory approval for two of its AI-powered cancer diagnostic software in South Korea. In 2020, they received clearance for DeepDx®-Prostate, a software that aids pathologists in diagnosing prostate cancer by detecting malignant lesions. In 2021, they obtained regulatory clearance for DeepDx®-Prostate Pro, a software that assists pathologists in grading and measuring tumors in prostate biopsies.
As a trailblazer in AI-based pathology image analysis and cancer diagnostic software in Korea, Deep Bio continues to expand its global presence through partnerships with digital pathology platform providers in the US, Europe, and India. The company also engages in collaborative research with leading US research institutions, including Stanford Medical School and Harvard Dana-Farber Cancer Institute. Deep Bio's groundbreaking clinical research results have been published in prestigious medical journals, such as Cancers and npj Digital Medicine.
About Deep Bio
Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio's vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit http://www.deepbio.co.kr.
DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit http://www.deepbio.co.kr.
HOICHANG CHUNG, Deep Bio Inc., http://www.deepbio.co.kr, 82 010-2796-5070, [email protected]
Share this article